U.S. Biotech Stock News

Crane (CR) is back in focus after a quarterly operating update that detailed segment performance, manufacturing efficiency, and a routine distribution announcement, prompting investors to reassess the stock following a strong multiyear total return profile. See our latest analysis for Crane. At a share price of $200.52, Crane’s 90 day share price return of 11.72% and year to date share price return of 6.93% sit alongside a 1 year total shareholder return of 17.54% and very strong multi year...

Why Regency Centers Is Back on Investor Radars Regency Centers (REG) has drawn fresh attention after reporting fourth quarter and full year 2025 results that showed higher sales, revenue, and net income, alongside new 2026 earnings guidance outlining management's expectations. See our latest analysis for Regency Centers. At a share price of US$76.18, Regency Centers has logged a 30 day share price return of 6.59% and a 90 day share price return of 9.63%. Its 5 year total shareholder return of...

In recent weeks, Disney has taken legal action against ByteDance, issuing a cease-and-desist letter that challenges the use of Disney characters and other intellectual property in training ByteDance’s AI video generator, Seedance 2.0, as generative AI tools spread across online platforms. This dispute highlights how Disney is actively testing and defending new licensing models for its content in the AI era, especially after its separate deal allowing OpenAI to use Disney IP in AI video...

DigitalOcean Holdings (DOCN) is back in focus after a recent upgrade to Overweight, as Cantor Fitzgerald highlighted the company’s progress in scaling its cloud platform and attracting larger customers such as Character.ai. See our latest analysis for DigitalOcean Holdings. The upgrade appears to have come as momentum was already building, with a 1 month share price return of 29.19%, a 90 day share price return of 54.87%, and a 1 year total shareholder return of 53.13% pointing to strong...

Azenta stock performance snapshot after recent moves Azenta (AZTA) has seen mixed returns recently, with the share price up 1.8% over the past day but down over the past week, month, past 3 months and year. See our latest analysis for Azenta. That 1.8% one day share price gain comes after a tougher stretch, with a 30 day share price return of 28.45% and a 1 year total shareholder return of 36.97%. This suggests momentum has been fading rather than building. If Azenta's recent weakness has you...

What recent performance says about New Oriental Education & Technology Group New Oriental Education & Technology Group (EDU) has drawn investor attention after a period where the stock moved roughly 6% over the past month and about 10% over the past 3 months. Those returns sit alongside a 1 day decline of about 2.6% and a 7 day decline of roughly 2.3%. This combination can prompt investors to look more closely at the company’s fundamentals and recent financial metrics. See our latest analysis...

Exelixis recently reported past fourth-quarter 2025 revenue of US$598.66 million and net income of US$244.53 million, with full-year 2025 revenue of US$2.32 billion and net income of US$782.57 million, alongside higher basic and diluted earnings per share from continuing operations versus the prior year. At the same time, the FDA accepted Exelixis’s New Drug Application for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, signaling regulatory progress that...

In recent months, Quantum Computing Inc. completed the US$110.0 million cash acquisition of Luminar Semiconductor, expanding its photonic technology portfolio, patent base and engineering capabilities to better address government and defense-related demand. At the same time, Quantum Computing Inc. has become one of the most heavily shorted mid-to-mega cap technology names, with very large short interest intensifying attention on its limited revenues, frequent equity raises and insider...

Relay Therapeutics recently announced that the U.S. FDA granted Breakthrough Therapy designation to its PI3Kα inhibitor zovegalisib (RLY-2608) in combination with fulvestrant for adults with PIK3CA‑mutant HR+/HER2‑ locally advanced or metastatic breast cancer after CDK4/6 inhibitor treatment, supported by Phase 1/2 ReDiscover trial data and an ongoing Phase 3 study. This regulatory milestone not only accelerates FDA feedback and review timelines but also highlights zovegalisib’s potential...

What IPG Photonics’ recent performance could mean for investors IPG Photonics (IPGP) has drawn attention after a strong run, with the stock showing gains over the past week, month and past 3 months, alongside reported annual revenue of US$1,003.8m and net income of US$31.1m. See our latest analysis for IPG Photonics. The recent surge in IPG Photonics’ share price, with a 30 day share price return of 88.3% and a year to date share price return of 105.7%, contrasts with a 5 year total...

Agilent Technologies (A) just secured U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx test in first line ovarian and related cancers, extending the assay’s use as a companion diagnostic for Merck’s Keytruda. See our latest analysis for Agilent Technologies. Agilent’s latest FDA approval and ongoing automation push come while the 1 month share price return of 9.9% decline and 3 year total shareholder return of 13.24% decline signal pressure on both short and long term performance, suggesting...

In the third quarter, Allianz Asset Management GmbH initiated a new position in Ingevity, purchasing 30,268 shares valued at approximately US$1,670,000, alongside broader institutional trading that has brought institutional ownership to 91.59% of the company’s stock. Along with this high level of institutional participation, Ingevity’s recent quarterly earnings release has drawn heightened attention to how professional investors may be repositioning ahead of evolving fundamentals. With...

Blackbaud (BLKB) has just reported a return to profitability for both the fourth quarter and full year 2025, achieved its Rule of 40 goal earlier than planned, and issued new revenue guidance for 2026. See our latest analysis for Blackbaud. Despite the earnings rebound and early Rule of 40 achievement, Blackbaud’s recent share price performance has been weak, with a 30 day share price return showing an 11.54% decline and a 1 year total shareholder return showing a 38.56% loss. This suggests...

Keurig Dr Pepper recently expanded its Board of Directors to eleven members by appointing two independent directors, Alphabet finance executive Amie Thuener and former Constellation Brands CEO Bill Newlands, and restructured its committees by replacing the Remuneration & Nominating Committee with separate Nominating & Governance and Compensation Committees. These governance changes arrive as Keurig Dr Pepper prepares to close the JDE Peet’s acquisition and progress toward splitting into two...

UGI (UGI) is in the spotlight after its latest quarter showed earnings per share moving down while segment EBIT grew, alongside ongoing LPG divestitures, fresh leadership and continued capital returns to shareholders. See our latest analysis for UGI. UGI’s share price has been firming up, with an 11.0% 90 day share price return and a 25.29% 1 year total shareholder return. This suggests recent earnings, buybacks and leadership changes are starting to reshape sentiment around the stock’s risk...

India’s competition regulator fined Intel for anti-competitive warranty practices tied to India specific terms on certain products. Intel has paid the penalty, withdrawn the policy, and is required to publicize the change across the Indian market. New CEO Lip-Bu Tan is repositioning NasdaqGS:INTC around AI, high end compute, and foundry services while addressing regulatory and operational challenges. For you as an investor watching NasdaqGS:INTC, this mix of regulatory action and leadership...

If you are looking at Louisiana-Pacific and asking whether the current share price lines up with the underlying business, you are in the right place. The stock closed at US$93.62, with a 5.0% decline over the last 7 days, a 0.5% return over 30 days, a 14.5% return year to date, and returns of a 15.7% decline over 1 year, 50.3% over 3 years, and 110.4% over 5 years. These mixed returns hint that the market has been reassessing both the potential and the risks around Louisiana-Pacific. To...

Sprinklr: recent performance snapshot Sprinklr (CXM) has been on the radar for its recent share performance, with the stock around $5.49 and returns showing pressure over the past month, the past 3 months, and over the past year. See our latest analysis for Sprinklr. With the share price at US$5.49, Sprinklr’s recent 1 day share price return of 1.86% comes after a softer patch. The 30 day share price return of 17.07% and 1 year total shareholder return of 38.86% may suggest fading momentum...

In February 2026, International Flavors & Fragrances Inc. reported mixed fourth-quarter 2025 results, with sales of US$2,589 million down from US$2,771 million a year earlier, a swing to full-year 2025 net loss of US$374 million, and issued 2026 sales guidance of US$10.50–US$10.80 billion alongside adjusted EBITDA guidance of US$2.05–US$2.15 billion. At the same time, IFF accelerated its portfolio reshaping by launching a formal sale process for its Food Ingredients business and outlining a...

Why Zimmer Biomet stock is back in focus Zimmer Biomet Holdings (ZBH) is back on investors radar after fourth quarter and full year 2025 results topped revenue and profit expectations, supported by hip and knee demand and progress in robotic assisted surgical systems. See our latest analysis for Zimmer Biomet Holdings. The recent results and fresh US$1.5b buyback authorization have coincided with a 7.5% 7 day share price return and 10.5% 30 day share price return. However, the 1 year total...

Recent performance context for Braze Braze (BRZE) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months, year to date, and over the past year. See our latest analysis for Braze. With the share price at $17.60, Braze’s recent momentum has been weak, with a 30 day share price return of 23.58% and a 1 year total shareholder return of 57.60%. This points to fading sentiment and higher perceived risk...

Ocular Therapeutix reported fourth-quarter 2025 revenue of US$13.25 million and a net loss of US$64.65 million, and filed an US$8.29 million shelf registration for 974,000 common shares tied to its employee stock plans. The company also recently hosted a webcast to share topline Phase 3 SOL-1 data for its investigational AXPAXLI therapy in wet age-related macular degeneration, a program that could materially influence its long-term pipeline value and competitive positioning in retinal...

In early February 2026, Atmos Energy shareholders approved extensive amendments to the company’s charters and bylaws, including lifting authorized common shares to 400 million and updating rules on director elections, officer liability, indemnification, meeting procedures, and legal forums. These governance changes, together with the board’s alignment on modernized bylaws, give Atmos Energy greater flexibility for future capital raising and corporate actions while tightening legal and...

IBM (NYSE:IBM) is under heavier scrutiny from investors and industry analysts over its artificial intelligence strategy. Prominent short sellers have publicly criticized IBM's positioning and execution in AI. At the same time, IBM is launching new AI driven products, including a next generation FlashSystem with agentic AI features. The company is also expanding hiring for entry level roles tied to AI focused work and next generation tech skills. For you as an investor, this mix of criticism...